The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Live Attenuated Influenza Vaccine (LAIV) Market Research Report 2025
Synopsis
A Live Attenuated Influenza Vaccine (LAIV), also known as the "nasal spray" or "intranasal" flu vaccine, is a type of influenza vaccine that is designed to provide immunity against the influenza virus. Unlike traditional injectable influenza vaccines, which contain inactivated (killed) virus particles, LAIV contains a weakened, live influenza virus. This live virus is attenuated, meaning it has been modified to reduce its virulence (ability to cause disease) while still retaining the capacity to stimulate an immune response.
The global Live Attenuated Influenza Vaccine (LAIV) market was valued at US$ 7740.5 million in 2023 and is anticipated to reach US$ 11700 million by 2030, witnessing a CAGR of 6.3% during the forecast period 2024-2030.
Evolving Vaccine Formulations: The LAIV formulation changes annually to match the prevalent influenza virus strains. Researchers continually monitor and adapt the vaccine to ensure it provides protection against the most relevant strains. This requires ongoing research and development efforts.
Preference for Non-Invasive Vaccination: The nasal spray administration method of LAIV is preferred by some individuals, particularly children and those who are averse to needles. This preference has driven demand for LAIV, especially among pediatric populations.
Efficacy and Effectiveness Research: Ongoing research is aimed at improving the effectiveness and stability of LAIV. Ensuring the vaccine's effectiveness is crucial in maintaining public confidence and its role in influenza prevention.
Enhanced Cold Chain Management: As LAIV is a live vaccine, it requires specific storage and transport conditions to maintain its viability. Advances in cold chain management are essential to preserve the vaccine's effectiveness.
Global Variations in Approval: Approval and recommendations for LAIV can vary by country and region. Some countries may be more enthusiastic about LAIV, while others may have specific guidelines and restrictions regarding its use.
This report aims to provide a comprehensive presentation of the global market for Live Attenuated Influenza Vaccine (LAIV), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Live Attenuated Influenza Vaccine (LAIV).
Report Scope
The Live Attenuated Influenza Vaccine (LAIV) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Live Attenuated Influenza Vaccine (LAIV) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Live Attenuated Influenza Vaccine (LAIV) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
Cytiva
BioDiem
FluMist
GSK
ChangChun High & New Technology
BCHT Biotechnology
Segment by Type
Trivalent Flu Vaccine
Quadrivalent Flu Vaccine
Segment by Application
Hospital
Clinic
Public Health Agency
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Live Attenuated Influenza Vaccine (LAIV) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Live Attenuated Influenza Vaccine (LAIV) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
A Live Attenuated Influenza Vaccine (LAIV), also known as the "nasal spray" or "intranasal" flu vaccine, is a type of influenza vaccine that is designed to provide immunity against the influenza virus. Unlike traditional injectable influenza vaccines, which contain inactivated (killed) virus particles, LAIV contains a weakened, live influenza virus. This live virus is attenuated, meaning it has been modified to reduce its virulence (ability to cause disease) while still retaining the capacity to stimulate an immune response.
The global Live Attenuated Influenza Vaccine (LAIV) market was valued at US$ 7740.5 million in 2023 and is anticipated to reach US$ 11700 million by 2030, witnessing a CAGR of 6.3% during the forecast period 2024-2030.
Evolving Vaccine Formulations: The LAIV formulation changes annually to match the prevalent influenza virus strains. Researchers continually monitor and adapt the vaccine to ensure it provides protection against the most relevant strains. This requires ongoing research and development efforts.
Preference for Non-Invasive Vaccination: The nasal spray administration method of LAIV is preferred by some individuals, particularly children and those who are averse to needles. This preference has driven demand for LAIV, especially among pediatric populations.
Efficacy and Effectiveness Research: Ongoing research is aimed at improving the effectiveness and stability of LAIV. Ensuring the vaccine's effectiveness is crucial in maintaining public confidence and its role in influenza prevention.
Enhanced Cold Chain Management: As LAIV is a live vaccine, it requires specific storage and transport conditions to maintain its viability. Advances in cold chain management are essential to preserve the vaccine's effectiveness.
Global Variations in Approval: Approval and recommendations for LAIV can vary by country and region. Some countries may be more enthusiastic about LAIV, while others may have specific guidelines and restrictions regarding its use.
This report aims to provide a comprehensive presentation of the global market for Live Attenuated Influenza Vaccine (LAIV), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Live Attenuated Influenza Vaccine (LAIV).
Report Scope
The Live Attenuated Influenza Vaccine (LAIV) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Live Attenuated Influenza Vaccine (LAIV) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Live Attenuated Influenza Vaccine (LAIV) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
Cytiva
BioDiem
FluMist
GSK
ChangChun High & New Technology
BCHT Biotechnology
Segment by Type
Trivalent Flu Vaccine
Quadrivalent Flu Vaccine
Segment by Application
Hospital
Clinic
Public Health Agency
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Live Attenuated Influenza Vaccine (LAIV) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Live Attenuated Influenza Vaccine (LAIV) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Live Attenuated Influenza Vaccine (LAIV) Market Overview
1.1 Product Overview and Scope of Live Attenuated Influenza Vaccine (LAIV)
1.2 Live Attenuated Influenza Vaccine (LAIV) Segment by Type
1.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Value Comparison by Type (2024-2030)
1.2.2 Trivalent Flu Vaccine
1.2.3 Quadrivalent Flu Vaccine
1.3 Live Attenuated Influenza Vaccine (LAIV) Segment by Application
1.3.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Public Health Agency
1.3.5 Other
1.4 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Estimates and Forecasts
1.4.1 Global Live Attenuated Influenza Vaccine (LAIV) Revenue 2019-2030
1.4.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales 2019-2030
1.4.3 Global Live Attenuated Influenza Vaccine (LAIV) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Live Attenuated Influenza Vaccine (LAIV) Market Competition by Manufacturers
2.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Manufacturers (2019-2024)
2.4 Global Live Attenuated Influenza Vaccine (LAIV) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV), Product Type & Application
2.7 Live Attenuated Influenza Vaccine (LAIV) Market Competitive Situation and Trends
2.7.1 Live Attenuated Influenza Vaccine (LAIV) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Live Attenuated Influenza Vaccine (LAIV) Players Market Share by Revenue
2.7.3 Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Live Attenuated Influenza Vaccine (LAIV) Retrospective Market Scenario by Region
3.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Live Attenuated Influenza Vaccine (LAIV) Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region: 2019-2030
3.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region: 2019-2024
3.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region: 2025-2030
3.3 Global Live Attenuated Influenza Vaccine (LAIV) Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region: 2019-2030
3.3.1 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region: 2019-2024
3.3.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region: 2025-2030
3.4 North America Live Attenuated Influenza Vaccine (LAIV) Market Facts & Figures by Country
3.4.1 North America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2030)
3.4.3 North America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Live Attenuated Influenza Vaccine (LAIV) Market Facts & Figures by Country
3.5.1 Europe Live Attenuated Influenza Vaccine (LAIV) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2030)
3.5.3 Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Facts & Figures by Country
3.6.1 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2030)
3.6.3 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Live Attenuated Influenza Vaccine (LAIV) Market Facts & Figures by Country
3.7.1 Latin America Live Attenuated Influenza Vaccine (LAIV) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2030)
3.7.3 Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Facts & Figures by Country
3.8.1 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2019-2030)
4.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2019-2024)
4.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (2025-2030)
4.1.3 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2019-2030)
4.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2019-2030)
4.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2019-2024)
4.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Type (2025-2030)
4.2.3 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type (2019-2030)
4.3 Global Live Attenuated Influenza Vaccine (LAIV) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2019-2030)
5.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2019-2024)
5.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2025-2030)
5.1.3 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2019-2030)
5.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2019-2030)
5.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2019-2024)
5.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Application (2025-2030)
5.2.3 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application (2019-2030)
5.3 Global Live Attenuated Influenza Vaccine (LAIV) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Sanofi Pasteur
6.1.1 Sanofi Pasteur Corporation Information
6.1.2 Sanofi Pasteur Description and Business Overview
6.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Portfolio
6.1.5 Sanofi Pasteur Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 CSL
6.3.1 CSL Corporation Information
6.3.2 CSL Description and Business Overview
6.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 CSL Live Attenuated Influenza Vaccine (LAIV) Product Portfolio
6.3.5 CSL Recent Developments/Updates
6.4 Abbott
6.4.1 Abbott Corporation Information
6.4.2 Abbott Description and Business Overview
6.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Portfolio
6.4.5 Abbott Recent Developments/Updates
6.5 GlaxoSmithKline
6.5.1 GlaxoSmithKline Corporation Information
6.5.2 GlaxoSmithKline Description and Business Overview
6.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Portfolio
6.5.5 GlaxoSmithKline Recent Developments/Updates
6.6 Serum Institute
6.6.1 Serum Institute Corporation Information
6.6.2 Serum Institute Description and Business Overview
6.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Portfolio
6.6.5 Serum Institute Recent Developments/Updates
6.7 Fluenz Tetra
6.6.1 Fluenz Tetra Corporation Information
6.6.2 Fluenz Tetra Description and Business Overview
6.6.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Portfolio
6.7.5 Fluenz Tetra Recent Developments/Updates
6.8 Cytiva
6.8.1 Cytiva Corporation Information
6.8.2 Cytiva Description and Business Overview
6.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Portfolio
6.8.5 Cytiva Recent Developments/Updates
6.9 BioDiem
6.9.1 BioDiem Corporation Information
6.9.2 BioDiem Description and Business Overview
6.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)
6.9.4 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Portfolio
6.9.5 BioDiem Recent Developments/Updates
6.10 FluMist
6.10.1 FluMist Corporation Information
6.10.2 FluMist Description and Business Overview
6.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)
6.10.4 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Portfolio
6.10.5 FluMist Recent Developments/Updates
6.11 GSK
6.11.1 GSK Corporation Information
6.11.2 GSK Live Attenuated Influenza Vaccine (LAIV) Description and Business Overview
6.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)
6.11.4 GSK Live Attenuated Influenza Vaccine (LAIV) Product Portfolio
6.11.5 GSK Recent Developments/Updates
6.12 ChangChun High & New Technology
6.12.1 ChangChun High & New Technology Corporation Information
6.12.2 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Description and Business Overview
6.12.3 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)
6.12.4 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product Portfolio
6.12.5 ChangChun High & New Technology Recent Developments/Updates
6.13 BCHT Biotechnology
6.13.1 BCHT Biotechnology Corporation Information
6.13.2 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Description and Business Overview
6.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue and Gross Margin (2019-2024)
6.13.4 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Portfolio
6.13.5 BCHT Biotechnology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Live Attenuated Influenza Vaccine (LAIV) Industry Chain Analysis
7.2 Live Attenuated Influenza Vaccine (LAIV) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Live Attenuated Influenza Vaccine (LAIV) Production Mode & Process
7.4 Live Attenuated Influenza Vaccine (LAIV) Sales and Marketing
7.4.1 Live Attenuated Influenza Vaccine (LAIV) Sales Channels
7.4.2 Live Attenuated Influenza Vaccine (LAIV) Distributors
7.5 Live Attenuated Influenza Vaccine (LAIV) Customers
8 Live Attenuated Influenza Vaccine (LAIV) Market Dynamics
8.1 Live Attenuated Influenza Vaccine (LAIV) Industry Trends
8.2 Live Attenuated Influenza Vaccine (LAIV) Market Drivers
8.3 Live Attenuated Influenza Vaccine (LAIV) Market Challenges
8.4 Live Attenuated Influenza Vaccine (LAIV) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Live Attenuated Influenza Vaccine (LAIV) Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Live Attenuated Influenza Vaccine (LAIV) Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Live Attenuated Influenza Vaccine (LAIV) Market Competitive Situation by Manufacturers in 2023
Table 4. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Live Attenuated Influenza Vaccine (LAIV) Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Live Attenuated Influenza Vaccine (LAIV), Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV), Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV), Product Type & Application
Table 12. Global Key Manufacturers of Live Attenuated Influenza Vaccine (LAIV), Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Live Attenuated Influenza Vaccine (LAIV) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Attenuated Influenza Vaccine (LAIV) as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2019-2024) & (K Units)
Table 18. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2019-2024)
Table 19. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2025-2030) & (K Units)
Table 20. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2025-2030)
Table 21. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2019-2024)
Table 23. Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2025-2030)
Table 25. North America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2024) & (K Units)
Table 27. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2025-2030) & (K Units)
Table 28. North America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2024) & (K Units)
Table 32. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2025-2030) & (K Units)
Table 33. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K Units) by Type (2019-2024)
Table 51. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K Units) by Type (2025-2030)
Table 52. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2019-2024)
Table 53. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2025-2030)
Table 54. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type (2019-2024)
Table 57. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Type (2025-2030)
Table 58. Global Live Attenuated Influenza Vaccine (LAIV) Price (US$/Unit) by Type (2019-2024)
Table 59. Global Live Attenuated Influenza Vaccine (LAIV) Price (US$/Unit) by Type (2025-2030)
Table 60. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K Units) by Application (2019-2024)
Table 61. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K Units) by Application (2025-2030)
Table 62. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2019-2024)
Table 63. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2025-2030)
Table 64. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application (2019-2024)
Table 67. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Application (2025-2030)
Table 68. Global Live Attenuated Influenza Vaccine (LAIV) Price (US$/Unit) by Application (2019-2024)
Table 69. Global Live Attenuated Influenza Vaccine (LAIV) Price (US$/Unit) by Application (2025-2030)
Table 70. Sanofi Pasteur Corporation Information
Table 71. Sanofi Pasteur Description and Business Overview
Table 72. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product
Table 74. Sanofi Pasteur Recent Developments/Updates
Table 75. AstraZeneca Corporation Information
Table 76. AstraZeneca Description and Business Overview
Table 77. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product
Table 79. AstraZeneca Recent Developments/Updates
Table 80. CSL Corporation Information
Table 81. CSL Description and Business Overview
Table 82. CSL Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. CSL Live Attenuated Influenza Vaccine (LAIV) Product
Table 84. CSL Recent Developments/Updates
Table 85. Abbott Corporation Information
Table 86. Abbott Description and Business Overview
Table 87. Abbott Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Abbott Live Attenuated Influenza Vaccine (LAIV) Product
Table 89. Abbott Recent Developments/Updates
Table 90. GlaxoSmithKline Corporation Information
Table 91. GlaxoSmithKline Description and Business Overview
Table 92. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product
Table 94. GlaxoSmithKline Recent Developments/Updates
Table 95. Serum Institute Corporation Information
Table 96. Serum Institute Description and Business Overview
Table 97. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product
Table 99. Serum Institute Recent Developments/Updates
Table 100. Fluenz Tetra Corporation Information
Table 101. Fluenz Tetra Description and Business Overview
Table 102. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product
Table 104. Fluenz Tetra Recent Developments/Updates
Table 105. Cytiva Corporation Information
Table 106. Cytiva Description and Business Overview
Table 107. Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Cytiva Live Attenuated Influenza Vaccine (LAIV) Product
Table 109. Cytiva Recent Developments/Updates
Table 110. BioDiem Corporation Information
Table 111. BioDiem Description and Business Overview
Table 112. BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. BioDiem Live Attenuated Influenza Vaccine (LAIV) Product
Table 114. BioDiem Recent Developments/Updates
Table 115. FluMist Corporation Information
Table 116. FluMist Description and Business Overview
Table 117. FluMist Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. FluMist Live Attenuated Influenza Vaccine (LAIV) Product
Table 119. FluMist Recent Developments/Updates
Table 120. GSK Corporation Information
Table 121. GSK Description and Business Overview
Table 122. GSK Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. GSK Live Attenuated Influenza Vaccine (LAIV) Product
Table 124. GSK Recent Developments/Updates
Table 125. ChangChun High & New Technology Corporation Information
Table 126. ChangChun High & New Technology Description and Business Overview
Table 127. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product
Table 129. ChangChun High & New Technology Recent Developments/Updates
Table 130. BCHT Biotechnology Corporation Information
Table 131. BCHT Biotechnology Description and Business Overview
Table 132. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product
Table 134. BCHT Biotechnology Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Live Attenuated Influenza Vaccine (LAIV) Distributors List
Table 138. Live Attenuated Influenza Vaccine (LAIV) Customers List
Table 139. Live Attenuated Influenza Vaccine (LAIV) Market Trends
Table 140. Live Attenuated Influenza Vaccine (LAIV) Market Drivers
Table 141. Live Attenuated Influenza Vaccine (LAIV) Market Challenges
Table 142. Live Attenuated Influenza Vaccine (LAIV) Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Live Attenuated Influenza Vaccine (LAIV)
Figure 2. Global Live Attenuated Influenza Vaccine (LAIV) Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Type in 2023 & 2030
Figure 4. Trivalent Flu Vaccine Product Picture
Figure 5. Quadrivalent Flu Vaccine Product Picture
Figure 6. Global Live Attenuated Influenza Vaccine (LAIV) Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application in 2023 & 2030
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Public Health Agency
Figure 11. Other
Figure 12. Global Live Attenuated Influenza Vaccine (LAIV) Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (2019-2030) & (US$ Million)
Figure 14. Global Live Attenuated Influenza Vaccine (LAIV) Sales (2019-2030) & (K Units)
Figure 15. Global Live Attenuated Influenza Vaccine (LAIV) Average Price (US$/Unit) & (2019-2030)
Figure 16. Live Attenuated Influenza Vaccine (LAIV) Report Years Considered
Figure 17. Live Attenuated Influenza Vaccine (LAIV) Sales Share by Manufacturers in 2023
Figure 18. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest Live Attenuated Influenza Vaccine (LAIV) Players: Market Share by Revenue in 2023
Figure 20. Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country (2019-2030)
Figure 23. North America Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country (2019-2030)
Figure 24. United States Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country (2019-2030)
Figure 27. Europe Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country (2019-2030)
Figure 28. Germany Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Russia Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2019-2030)
Figure 35. China Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. China Taiwan Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Indonesia Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Thailand Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Malaysia Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Latin America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country (2019-2030)
Figure 45. Latin America Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country (2019-2030)
Figure 46. Mexico Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Brazil Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Argentina Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country (2019-2030)
Figure 50. Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Country (2019-2030)
Figure 51. Turkey Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. UAE Live Attenuated Influenza Vaccine (LAIV) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Global Sales Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type (2019-2030)
Figure 55. Global Revenue Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type (2019-2030)
Figure 56. Global Live Attenuated Influenza Vaccine (LAIV) Price (US$/Unit) by Type (2019-2030)
Figure 57. Global Sales Market Share of Live Attenuated Influenza Vaccine (LAIV) by Application (2019-2030)
Figure 58. Global Revenue Market Share of Live Attenuated Influenza Vaccine (LAIV) by Application (2019-2030)
Figure 59. Global Live Attenuated Influenza Vaccine (LAIV) Price (US$/Unit) by Application (2019-2030)
Figure 60. Live Attenuated Influenza Vaccine (LAIV) Value Chain
Figure 61. Live Attenuated Influenza Vaccine (LAIV) Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
